BR0014374A - Combinação de loteprednol e agonistas do adrenorreceptor beta dois - Google Patents

Combinação de loteprednol e agonistas do adrenorreceptor beta dois

Info

Publication number
BR0014374A
BR0014374A BR0014374-0A BR0014374A BR0014374A BR 0014374 A BR0014374 A BR 0014374A BR 0014374 A BR0014374 A BR 0014374A BR 0014374 A BR0014374 A BR 0014374A
Authority
BR
Brazil
Prior art keywords
combination
loteprednol
beta
drugs
adrenoreceptor agonists
Prior art date
Application number
BR0014374-0A
Other languages
English (en)
Other versions
BR0014374B1 (pt
Inventor
Istvan Szelenyi
Hildegard Kuss
Sabine Heer
Juergen Engel
Original Assignee
Viatris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh filed Critical Viatris Gmbh
Publication of BR0014374A publication Critical patent/BR0014374A/pt
Publication of BR0014374B1 publication Critical patent/BR0014374B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Patente de Invenção: "COMBINAçãO DE LOTEPREDNOL E AGONISTAS DO ADRENORRECEPTOR BETA DOIS". A invenção refere-se a uma nova combinação de um esteróide suave, de modo específico o loteprednol, e pelo menos um agonista do adrenorreceptor <225>2, para o tratamento simultâneo, em seq³ência ou separado de alergias e/ou distúrbios das vias aéreas, os medicamentos compreendendo a combinação, processos para a produção de tais medicamentos e o uso da nova combinação para a produção de medicamentos para o tratamento simultâneo, em seq³ência ou separado de alergias e/ou de distúrbios das vias aéreas.
BRPI0014374-0A 1999-09-30 2000-09-26 preparaÇço farmacÊutica, medicamento, processo para produÇço de dito medicamento e uso de uma combinaÇço de loteprednol e agonistas do adrenorreceptor beta dois. BR0014374B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19947235A DE19947235A1 (de) 1999-09-30 1999-09-30 Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten
PCT/EP2000/009392 WO2001022956A2 (de) 1999-09-30 2000-09-26 NEUE KOMBINATION VON LOTEPREDNOL UND β2-ADRENOZEPTOR-AGONISTEN

Publications (2)

Publication Number Publication Date
BR0014374A true BR0014374A (pt) 2002-06-25
BR0014374B1 BR0014374B1 (pt) 2012-12-25

Family

ID=7924101

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0014374-0A BR0014374B1 (pt) 1999-09-30 2000-09-26 preparaÇço farmacÊutica, medicamento, processo para produÇço de dito medicamento e uso de uma combinaÇço de loteprednol e agonistas do adrenorreceptor beta dois.

Country Status (20)

Country Link
US (1) US7521438B1 (pt)
EP (1) EP1216047B1 (pt)
JP (1) JP5068912B2 (pt)
AR (1) AR025924A1 (pt)
AT (1) ATE306271T1 (pt)
AU (1) AU7907400A (pt)
BR (1) BR0014374B1 (pt)
CA (1) CA2389111C (pt)
CY (1) CY1105548T1 (pt)
CZ (1) CZ296396B6 (pt)
DE (2) DE19947235A1 (pt)
DK (1) DK1216047T3 (pt)
EE (1) EE05050B1 (pt)
ES (1) ES2248131T3 (pt)
HU (1) HUP0202753A3 (pt)
MX (1) MXPA02003329A (pt)
PL (1) PL196729B1 (pt)
SI (1) SI1216047T1 (pt)
TW (1) TWI253930B (pt)
WO (1) WO2001022956A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US20090246281A1 (en) * 2003-11-03 2009-10-01 Norton Healthcare Ltd. Soft steroid compositions for use in dry powder inhalers
EP2221048A1 (en) * 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmaceutical composition for inhalation
US9238144B2 (en) * 2013-03-14 2016-01-19 Neuropace, Inc. Optimizing data retrieval from an active implantable medical device
WO2022016150A1 (en) * 2020-07-17 2022-01-20 Ross Peter M Methods for the treatment of cytokine release syndromes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB416950A (en) * 1933-07-28 1934-09-25 Ambrose Heal An improved support member for beds, settees, wardrobes and other articles of furniture
US4710495A (en) 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
ZA814440B (en) * 1980-07-10 1982-10-27 Otsuka Pharma Co Ltd Soft steroids having anti-inflammatory activity
TW503113B (en) * 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
DK1014943T3 (da) * 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
US5830490A (en) 1997-04-04 1998-11-03 Weinstein; Robert E. Method and device for organizing and coordinating the combined use of topical aerosols and oral medications for the treatment of disorders
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation

Also Published As

Publication number Publication date
BR0014374B1 (pt) 2012-12-25
CY1105548T1 (el) 2010-07-28
CA2389111A1 (en) 2001-04-05
US7521438B1 (en) 2009-04-21
PL353487A1 (en) 2003-11-17
EE200200163A (et) 2003-04-15
EE05050B1 (et) 2008-08-15
WO2001022956A3 (de) 2001-10-11
WO2001022956A2 (de) 2001-04-05
SI1216047T1 (sl) 2006-02-28
AU7907400A (en) 2001-04-30
AR025924A1 (es) 2002-12-18
DE19947235A1 (de) 2001-04-05
MXPA02003329A (es) 2004-09-10
EP1216047A2 (de) 2002-06-26
EP1216047B1 (de) 2005-10-12
JP2003510276A (ja) 2003-03-18
DK1216047T3 (da) 2006-02-13
DE50011340D1 (de) 2006-02-23
HUP0202753A2 (hu) 2002-12-28
CZ20021095A3 (cs) 2002-08-14
PL196729B1 (pl) 2008-01-31
ATE306271T1 (de) 2005-10-15
CZ296396B6 (cs) 2006-03-15
JP5068912B2 (ja) 2012-11-07
TWI253930B (en) 2006-05-01
CA2389111C (en) 2009-04-14
ES2248131T3 (es) 2006-03-16
HUP0202753A3 (en) 2004-06-28

Similar Documents

Publication Publication Date Title
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
CL2010000018A1 (es) Fragmentos de peptido amiloide beta(ab) ab 1-7 y ab 3-7 ligados a un peptido portador, composicion farmaceutica que lo comprende y su uso para tratar la enfermedad de alzheimer
BR0011891A (pt) Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
WO2000008015A3 (en) Fsh mimetics for the treatment of infertility
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
FR2827500B1 (fr) Plaque d&#39;osteosynthese de l&#39;extremite superieure de l&#39;humerus
BR9713914A (pt) Composto, uso do mesmo, composição farmacêutica, e processo para tratar um paciente sofrendo de um distúrbio que é susceptìvel a tratamento com um agonista da trombopoietina.
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
IL132661A0 (en) Agonists specific for the peripheral cannabinoid receptor
BR9809951A (pt) Método para tratamento da obesidade
BR0014384A (pt) Compostos para o tratamento da isquémia
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
YU7797A (sh) Kombinovana terapija za osteoporozu
BR0014312A (pt) Combinação de loteprednol e anti-histaminas
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
BR9910329A (pt) Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
WO2001076638A3 (en) Compositions for drug delivery
BR0211932A (pt) Métodos e composições para administração oral de hormÈnio de paratireóide, pth
BR0014374A (pt) Combinação de loteprednol e agonistas do adrenorreceptor beta dois
ZA988095B (en) New peptide mimetics for the treatment of bone metabolic disorders, methods for their production, and drugs containing these compounds.
BR9811465A (pt) N-triazolil-2-indolcarboxamidas e sua utilização como agonistas de cck-a.
SE9603725D0 (sv) New teatment

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: VIATRIS GMBH AND CO. KG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020050037237/RJ DE 17/05/2005.

B25D Requested change of name of applicant approved

Owner name: MEDA PHARMA GMBH AND CO. KG (DE)

Free format text: ALTERADO DE: VIATRIS GMBH AND CO. KG

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/12/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2325 DE 28-07-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.